RE
INDP icon

RBC Europe’s Indaptus Therapeutics INDP Stock Holding History

RBC Europe’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2
Closed -$995 – 1169
2020
Q3 		$995 Hold
2
– – ﹤0.01% 1023
2020
Q2 		$1.12K Hold
2
– – ﹤0.01% 984
2020
Q1 		$779 Hold
2
– – ﹤0.01% 966
2019
Q4 		$1.98K Hold
2
– – ﹤0.01% 962
2019
Q3 		$2.88K Buy
2
+1
+100% +$2.98K ﹤0.01% 937
2019
Q2 		$13.3K Hold
1
– – ﹤0.01% 743
2019
Q1 		$16.9K Hold
1
– – ﹤0.01% 691
2018
Q4 		$13.3K Buy
+1
New +$13.6K ﹤0.01% 720

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HAG
HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBC Europe's INDP Position: Q4 2020 in Review

RBC Europe sold out of Indaptus Therapeutics (INDP) in Q4 2020, closing a stake of 2 shares — an estimated $995 sold.

RBC Europe first reported a position in INDP in Q4 2018 and held it in 8 quarters. The position peaked at $16.9K in Q1 2019. 18 funds tracked by Wall St. Rank hold INDP as of Q4 2020.

  • RBC Europe reported no remaining Indaptus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • RBC Europe sold 2 Indaptus Therapeutics shares in Q4 2020, an estimated $995.
  • RBC Europe first reported a position in Indaptus Therapeutics in Q4 2018 and held it in 8 quarters.
  • RBC Europe's Indaptus Therapeutics position peaked at $16.9K in Q1 2019.
  • 18 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2020.

Based on RBC Europe's 13F filing for Q4 2020, filed 9 Nov 2023.